16,800 Shares in uniQure N.V. $QURE Purchased by Patriot Financial Group Insurance Agency LLC

Patriot Financial Group Insurance Agency LLC purchased a new position in shares of uniQure N.V. (NASDAQ:QURE) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 16,800 shares of the biotechnology company’s stock, valued at approximately $275,000.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in uniQure by 15.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock valued at $65,673,000 after buying an additional 152,417 shares during the period. Aberdeen Group plc boosted its stake in uniQure by 25.1% during the fourth quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock worth $88,030,000 after buying an additional 738,897 shares during the period. Quinn Opportunity Partners LLC acquired a new stake in shares of uniQure during the third quarter valued at about $6,281,000. Farallon Capital Management LLC increased its position in shares of uniQure by 3,935.7% during the third quarter. Farallon Capital Management LLC now owns 565,000 shares of the biotechnology company’s stock valued at $32,979,000 after acquiring an additional 551,000 shares during the last quarter. Finally, Boone Capital Management LLC purchased a new stake in shares of uniQure in the 3rd quarter valued at approximately $8,599,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Insider Transactions at uniQure

In other news, Director Madhavan Balachandran sold 11,685 shares of uniQure stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $45.06, for a total value of $526,526.10. Following the completion of the transaction, the director owned 43,254 shares in the company, valued at approximately $1,949,025.24. This trade represents a 21.27% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kylie O’keefe sold 15,936 shares of the business’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $27.06, for a total value of $431,228.16. Following the transaction, the insider directly owned 108,864 shares of the company’s stock, valued at approximately $2,945,859.84. This represents a 12.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 412,147 shares of company stock valued at $16,992,736 in the last 90 days. Insiders own 4.65% of the company’s stock.

Key uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $80 price target while raising multiple earnings estimates for uniQure, including near- and longer-term forecasts. The improved outlook suggests analysts see stronger future profitability than before. uniQure analyst update
• Positive Sentiment: Recent technical coverage highlighted that QURE is trading above a golden cross, which traders often view as a bullish momentum signal and a possible support level. Zacks golden cross article
• Neutral Sentiment: Media attention also included a comparison piece on uniQure versus Viridian Therapeutics and a short-squeeze watchlist mention, which may be adding trading interest but does not directly change fundamentals. AAII comparison article
• Negative Sentiment: Director Jack Kaye and insider Walid Abi-Saab both sold shares in recent SEC filings. Although the trades were made under pre-arranged 10b5-1 plans, insider selling can still weigh on sentiment. Jack Kaye SEC filing Walid Abi-Saab SEC filing

uniQure Price Performance

Shares of QURE opened at $41.81 on Friday. The company has a market cap of $2.64 billion, a P/E ratio of -12.01 and a beta of 0.90. uniQure N.V. has a fifty-two week low of $8.73 and a fifty-two week high of $71.50. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33. The firm’s 50 day moving average price is $30.05 and its 200 day moving average price is $23.73.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.03. The company had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. On average, research analysts forecast that uniQure N.V. will post -3.63 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on QURE. Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Weiss Ratings reissued a “sell (e+)” rating on shares of uniQure in a research report on Friday, June 26th. The Goldman Sachs Group boosted their target price on uniQure from $14.00 to $46.00 and gave the company a “neutral” rating in a research report on Thursday, June 18th. Stifel Nicolaus set a $28.00 price target on uniQure in a research note on Tuesday, May 5th. Finally, Barclays upgraded uniQure from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $25.00 to $65.00 in a research report on Thursday, June 18th. Twelve research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, uniQure presently has an average rating of “Moderate Buy” and an average price target of $64.17.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.